{"id":46264,"date":"2022-07-18T14:02:03","date_gmt":"2022-07-18T12:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/"},"modified":"2022-07-18T14:02:03","modified_gmt":"2022-07-18T12:02:03","slug":"mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/","title":{"rendered":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)"},"content":{"rendered":"
\n

\nVIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC)<\/i>\n<\/p>\n

\nVIVJOA is now available in a network of partner pharmacies that includes mail order and local pickup options<\/i>\n<\/p>\n

DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc.<\/a> (\u201cMycovia\u201d), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced U.S. availability of VIVJOA\u2122 (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.\n<\/p>\n

<\/a><\/p>\n

\nAs the first and only medication approved by the U.S. Food and Drug Administration for RVVC, commonly known as chronic yeast infection, a 12-week course of VIVJOA provides sustained efficacy demonstrated by significant long-term reduction of RVVC recurrence for nearly a year (50 weeks) versus comparators.\n<\/p>\n

\n\u201cThe Mycovia team has worked tirelessly to bring VIVJOA to commercial availability, and we feel immense reward in this achievement today because of the patients we may serve,\u201d said Patrick Jordan, CEO of Mycovia and Managing Partner at NovaQuest Capital Management. \u201cWe are ready to execute our launch strategy with clear objectives to reach appropriate RVVC patients and fulfill this previously unmet medical need among women suffering from chronic yeast infection.\u201d\n<\/p>\n

\nPotential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons\/conditions.\n<\/p>\n

\n\u201cThrough our efforts, we will help patients understand that chronic yeast infection is a distinct condition from acute yeast infection, and VIVJOA was designed and studied in clinical trials to reduce the incidence of recurrent vaginal yeast infection in females with a history of RVVC,\u201d added Tiffany Ahlers, Chief Commercial Officer of Mycovia. \u201cTo support effective two-way communication between patients and healthcare providers, we will encourage patients to ask their doctor if VIVJOA is right for them.\u201d\n<\/p>\n

\nMycovia\u2019s patient support program, My VIVJOA, powered by vitaCare, is a comprehensive program designed to help patients with insurance coverage support, seamlessly applied savings and ongoing education. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for branded medications. VitaCare will help patients understand and verify insurance coverage, identify available savings opportunities, assist providers in their communication with payors, and offer a seamless path for filling the VIVJOA prescription primarily through an appropriate mail order or local pharmacy partners.\n<\/p>\n

\nAbout Recurrent Vulvovaginal Candidiasis
\n
<\/b>RVVC is a debilitating, chronic infectious condition that affects 138 million women worldwide each year. RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection in 12 months. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain.\n<\/p>\n

\nAbout VIVJOA\u2122
\n
<\/b>VIVJOA\u2122 (oteseconazole) capsules are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. VIVJOA is the first and only FDA-approved medication that provides sustained efficacy demonstrated by significant long-term reduction of RVVC recurrence through 50 weeks versus comparators. Oteseconazole is designed to inhibit fungal CYP51, which is required for fungal cell wall integrity, and this selective interaction is also toxic to fungi, resulting in the inhibition of fungal growth. Due to its chemical structure, oteseconazole has a lower affinity for human CYP enzymes as compared to fungal CYP enzymes. The FDA approved VIVJOA based upon the positive results from three Phase 3 clinical trials of oteseconazole \u2013 two global VIOLET studies and one U.S.-focused ultraVIOLET study, including 875 patients at 232 sites across 11 countries.\n<\/p>\n

\nPlease click here<\/a> for full Prescribing Information.\n<\/p>\n

\nIMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n

\nCONTRAINDICATIONS
\n
<\/b>VIVJOA is contraindicated in females of reproductive potential. Females who are NOT of reproductive potential are defined as: persons who are biological females who are postmenopausal or have another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy).\n<\/p>\n

\nVIVJOA is contraindicated in pregnant and lactating women.\n<\/p>\n

\nVIVJOA is contraindicated in patients with known hypersensitivity to oteseconazole.\n<\/p>\n

\nWARNINGS AND PRECAUTIONS
\n
<\/b>Based on animal studies, VIVJOA may cause fetal harm. The drug exposure window of approximately 690 days (based on 5 times the half-life of oteseconazole) precludes adequate mitigation of the embryo-fetal toxicity risks. Advise patients that VIVJOA is contraindicated in females of reproductive potential, and in pregnant and lactating women because of potential risks to a fetus or breastfed infant.\n<\/p>\n

\nADVERSE REACTIONS
\n
<\/b>The most frequently reported adverse reactions among VIVJOA-treated patients in clinical studies included headache (7.4%) and nausea (3.6%).\n<\/p>\n

\nDRUG INTERACTIONS
\n
<\/b>VIVJOA is a Breast Cancer Resistance Protein (BCRP) inhibitor. Concomitant use of VIVJOA with BCRP substrates (e.g., rosuvastatin) may increase the exposure of BCRP substrates, which may increase the risk of adverse reactions associated with these drugs.\n<\/p>\n

\nPlease see full Prescribing Information<\/a> and Patient Information<\/a>.\n<\/p>\n

\nTo report SUSPECTED ADVERSE REACTIONS, contact Mycovia Pharmaceuticals, Inc. at 1-855-299-0637 or FDA at 1-800-FDA-1088 or <\/b>www.fda.gov\/medwatch<\/b><\/a>.<\/b>\n<\/p>\n

\nAbout Mycovia Pharmaceuticals
\n
<\/b>Mycovia Pharmaceuticals is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies. VIVJOA\u2122 (oteseconazole) capsules, the first FDA-approved product for Mycovia, are an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations to become the first FDA-approved therapy for RVVC. In 2019, Mycovia licensed oteseconazole to Jiangsu Hengrui Pharmaceuticals Co., Ltd., to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau and Taiwan, and Gedeon Richter Plc., a Hungary-based pharmaceutical company, to commercialize and manufacture oteseconazole in Europe, Russia, the Commonwealth of Independent States, Latin America and Australia. Mycovia also recognizes a tremendous potential for its oral fungal inhibitors and a growing need to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMycovia Pharmaceuticals, Inc.
\n
mediarelations@mycovia.com<\/a>\n<\/p>\n

\nMedia<\/b>
FleishmanHillard
\n
Elizabeth Comtois, 919-334-3786
\n
Elizabeth.comtois@fleishman.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC) VIVJOA is now available in a network of partner pharmacies that includes mail order and local pickup options DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (\u201cMycovia\u201d), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46264","6":"format-standard","7":"category-industry"},"yoast_head":"\nMycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC) VIVJOA is now available in a network of partner pharmacies that includes mail order and local pickup options DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (\u201cMycovia\u201d), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-18T12:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)\",\"datePublished\":\"2022-07-18T12:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/\"},\"wordCount\":1041,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005049\\\/en\\\/751062\\\/21\\\/mycovia-brand-rgb_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/\",\"name\":\"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005049\\\/en\\\/751062\\\/21\\\/mycovia-brand-rgb_%28002%29.jpg\",\"datePublished\":\"2022-07-18T12:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005049\\\/en\\\/751062\\\/21\\\/mycovia-brand-rgb_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220718005049\\\/en\\\/751062\\\/21\\\/mycovia-brand-rgb_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/","og_locale":"en_US","og_type":"article","og_title":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend","og_description":"VIVJOA is a new option for postmenopausal and permanently infertile women with recurrent vulvovaginal candidiasis (RVVC) VIVJOA is now available in a network of partner pharmacies that includes mail order and local pickup options DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (\u201cMycovia\u201d), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-18T12:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)","datePublished":"2022-07-18T12:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/"},"wordCount":1041,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/","url":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/","name":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg","datePublished":"2022-07-18T12:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220718005049\/en\/751062\/21\/mycovia-brand-rgb_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mycovia-pharmaceuticals-announces-u-s-availability-of-vivjoa-oteseconazole-capsules-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infect\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA\u2122 (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46264"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46264\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}